BR112023016241A2 - Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos - Google Patents

Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos

Info

Publication number
BR112023016241A2
BR112023016241A2 BR112023016241A BR112023016241A BR112023016241A2 BR 112023016241 A2 BR112023016241 A2 BR 112023016241A2 BR 112023016241 A BR112023016241 A BR 112023016241A BR 112023016241 A BR112023016241 A BR 112023016241A BR 112023016241 A2 BR112023016241 A2 BR 112023016241A2
Authority
BR
Brazil
Prior art keywords
metapneumovirus
antibodies
antigenic
bind
proteins
Prior art date
Application number
BR112023016241A
Other languages
English (en)
Portuguese (pt)
Inventor
Aimin Tang
Arthur Fridman
Hua-Poo Su
Dawn Galli Jennifer
Kalpit Vora
S Cox Kara
Lan Zhang
Xiao Xiao
Zhifeng Chen
Zhiyun Wen
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BR112023016241A2 publication Critical patent/BR112023016241A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112023016241A 2021-02-12 2022-02-08 Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos BR112023016241A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148920P 2021-02-12 2021-02-12
US202163276172P 2021-11-05 2021-11-05
PCT/US2022/015565 WO2022173714A2 (en) 2021-02-12 2022-02-08 Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof

Publications (1)

Publication Number Publication Date
BR112023016241A2 true BR112023016241A2 (pt) 2023-11-14

Family

ID=82838690

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016241A BR112023016241A2 (pt) 2021-02-12 2022-02-08 Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos

Country Status (9)

Country Link
US (1) US20240327502A1 (https=)
EP (1) EP4291232A4 (https=)
JP (1) JP2024512215A (https=)
KR (1) KR20230146047A (https=)
AU (1) AU2022220616A1 (https=)
BR (1) BR112023016241A2 (https=)
CA (1) CA3208018A1 (https=)
MX (1) MX2023009447A (https=)
WO (1) WO2022173714A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038512A1 (en) * 2023-08-17 2025-02-20 Merck Sharp & Dohme Llc Methods for detecting pcr chimeras
WO2025097674A1 (zh) * 2023-11-08 2025-05-15 安炎达医药技术(广州)有限公司 一种新型pace4抑制剂及其在抗骨关节炎中的应用
CN119143871B (zh) * 2024-11-20 2025-02-07 首都儿科研究所 用于人偏肺病毒检测的单克隆抗体、检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
JP2010505876A (ja) * 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
JP5642972B2 (ja) * 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
EP2445527A2 (en) * 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CA3138550A1 (en) * 2019-04-30 2020-11-05 Target Discovery Merger Sub II, LLC Cancer associated antibody compositions and methods of use

Also Published As

Publication number Publication date
WO2022173714A3 (en) 2022-11-10
AU2022220616A1 (en) 2023-08-31
WO2022173714A2 (en) 2022-08-18
KR20230146047A (ko) 2023-10-18
EP4291232A2 (en) 2023-12-20
EP4291232A4 (en) 2025-04-02
US20240327502A1 (en) 2024-10-03
CA3208018A1 (en) 2022-08-18
MX2023009447A (es) 2023-10-06
JP2024512215A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
BR112023016241A2 (pt) Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos
BR112019000798A2 (pt) anticorpos contra o vírus zika e método de uso
MX2024004936A (es) Variantes de capsides de aav y sus usos.
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112022015771A2 (pt) Compostos tetracíclicos para tratar a infecção por hiv
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
MX2024012807A (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
WO2022214678A3 (en) Human metapneumo virus vaccine
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
BR112022010425A2 (pt) Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
BR112021018409A2 (pt) Anticorpos e métodos para tratamento de infecção por influenza a
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
MX2020009296A (es) Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
BR112022010826A2 (pt) Anticorpos amplamente neutralizantes contra o hiv
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
BR112023019546A2 (pt) Anticorpos anti-tau e usos dos mesmos
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
MX2024005962A (es) Composiciones de proteínas de fusión inmunogénicas y métodos de uso de estas